Cibc World Markets Corp Acquires 2,201 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cibc World Markets Corp grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,153 shares of the biopharmaceutical company’s stock after purchasing an additional 2,201 shares during the quarter. Cibc World Markets Corp’s holdings in Regeneron Pharmaceuticals were worth $13,643,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of REGN. Principal Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the period. Golden State Equity Partners increased its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares during the period. Fagan Associates Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. ABC Arbitrage SA bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $1,510,000. Finally, Fisher Asset Management LLC boosted its position in Regeneron Pharmaceuticals by 16.5% during the fourth quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company’s stock valued at $4,197,000 after purchasing an additional 833 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on REGN. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $678.42 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market capitalization of $74.17 billion, a P/E ratio of 17.72, a PEG ratio of 2.34 and a beta of 0.27. The stock has a 50-day simple moving average of $694.15 and a two-hundred day simple moving average of $827.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business earned $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.